SCHEMBL5149167

SCHEMBL5149167

C#Cc1nc(-c2ccc(=O)n(C(C)C)n2)c(-c2ccccc2)nc1N

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.35
TP53 P04637 2/20 0.35
FGFR1 P11362 4/20 0.34
FGFR2 P21802 4/20 0.34
FGFR3 P22607 4/20 0.34
RET P07949 3/20 0.34
USP8 P40818 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE1C Q14123 1/20 0.33
POLB P06746 1/20 0.33
LMNA P02545 1/20 0.32
SRC P12931 2/20 0.32
ABL1 P00519 2/20 0.32
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
PIK3CG P48736 1/20 0.32
PRKDC P78527 1/20 0.32
P2RY6 Q15077 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147962 0.89 USP8 (0.46) ADORA2ATP53FGFR1FGFR2FGFR3
SCHEMBL5147922 0.89 USP8 (0.46) ADORA2ATP53FGFR1FGFR2FGFR3
SCHEMBL5152650 0.87 ABL1 (0.43) ADORA2ATP53RETPDE1APDE1B
SCHEMBL5149232 0.86 RET (0.35) ADORA2ATP53FGFR1FGFR2FGFR3
SCHEMBL5147958 0.86 ADORA2A (0.39) ADORA2ATP53FGFR1FGFR2FGFR3
SCHEMBL5149110 0.84 PDE1A (0.41) ADORA2ATP53FGFR1FGFR2FGFR3
SCHEMBL5149057 0.83 TP53 (0.36) ADORA2ATP53FGFR1FGFR2FGFR3
SCHEMBL5150753 0.83 ADORA2A (0.38) ADORA2ATP53FGFR1FGFR2FGFR3
SCHEMBL5148960 0.83 POLB (0.39) ADORA2ATP53FGFR1FGFR2FGFR3
SCHEMBL5149150 0.83 GRM5 (0.36) ADORA2ARETABL1PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
CN-1938296-A Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists ASTELLAS PHARMA INC (JP) 2007-03-28 CN disclosed
EP-1737841-A1 PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS Astellas Pharma Inc. (JP) 2007-01-03 EP disclosed
WO-2005095384-A1 PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS ASTELLAS PHARMA INC. (JP) 2005-10-13 WO disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 ADORA2A 1/4885TP53 2221/4885FGFR1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.